Altimmune (ALT)

Executive Summary

Altimmune is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for obesity and metabolic diseases. Its lead asset, pemvidutide, is a GLP-1/glucagon dual agonist that has demonstrated competitive weight loss and significant liver fat reduction in mid-stage trials. The company's proprietary platform enables the design of multi-agonist peptides with differentiated efficacy and safety profiles. With a market capitalization of approximately $508 million, Altimmune is well-positioned to address the growing demand for effective treatments in obesity and non-alcoholic steatohepatitis (NASH). Altimmune's pipeline includes pemvidutide in a Phase 2 trial for alcohol use disorder (AUD) with completion expected in mid-2026, and a completed Phase 2 trial in NASH that could yield data readout soon. The company also has earlier-stage assets in influenza and other indications. Key upcoming catalysts include top-line data from the AUD trial and potential disclosure of NASH Phase 2 results, which could significantly impact the company's valuation. While competition in the GLP-1 space is intense, pemvidutide's dual agonism offers a differentiated profile that may capture market share in both obesity and liver disease.

Upcoming Catalysts (preview)

• Q3 2026Pemvidutide Phase 2 AUD Top-Line Data50% success
• Q3 2026Pemvidutide NASH Phase 2 Results Disclosure60% success
• TBDPotential Partnership or Licensing Deal for Pemvidutide30% success